Serotonin Syndrome After Methylene Blue Administration During Cardiac Surgery: A Case Report and Review

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 30, Issue 4, 2016, Pages 1042-1045

  Wolvetang, Timothy ^a   Janse, Rineke ^a   ter Horst, Maarten ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cardiac surgery; methylene blue; postoperative hyperthermia; serotonin syndrome

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CLONAZEPAM; CREATINE KINASE; CREATININE; DESFLURANE; ESKETAMINE; GRANISETRON; HALOPERIDOL; METHYLENE BLUE; PAROXETINE; QUETIAPINE; VASOPRESSIN; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ADVERSE OUTCOME; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD EXAMINATION; CARDIOPULMONARY BYPASS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART SURGERY; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; LIVER FUNCTION TEST; MEDICAL HISTORY; MENTAL DETERIORATION; MIDDLE AGED; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; MUSCLE HYPERTONIA; MYDRIASIS; NYSTAGMUS; POSTOPERATIVE DELIRIUM; PRIORITY JOURNAL; SEROTONIN SYNDROME; VASOPLEGIA; CHEMICALLY INDUCED; POSTOPERATIVE COMPLICATION;

ANTIPSYCHOTIC AGENTS; CARDIAC SURGICAL PROCEDURES; FEMALE; HUMANS; METHYLENE BLUE; MIDDLE AGED; PAROXETINE; POSTOPERATIVE COMPLICATIONS; QUETIAPINE FUMARATE; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 84964668110     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2015.11.019     Document Type: Article

References (22)

1. 1 Rapport, M.M., Green, A.A., Page, I.H., : Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 176 (1948), 1243–1251.
2. 2 Boyer, E.W., Shannon, M., The serotonin syndrome. N Engl J Med 352 (2005), 1112–1120.
3. 3 Sternbach, H., The serotonin syndrome. Am J Psychiatry 148 (1991), 705–713.
4. 4 Dunkley, E.J., Isbister, G.K., Sibbritt, D., et al. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96 (2003), 635–642.
5. 5 Jiang, W., Impacts of depression and emotional distress on cardiac disease. Cleve Clin J Med 75 Suppl 2 (2008), S20–25.
6. 6 Fischer, G.W., Levin, M.A., Vasoplegia during cardiac surgery: Current concepts and management. Semin Thorac Cardiovasc Surg 22 (2010), 140–144.
7. 7 Lenglet, S., Mach, F., Montecucco, F., Methylene blue: Potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. Expert Rev Cardiovasc Ther 9 (2011), 1519–1525.
8. 8 Levin, R.L., Degrange, M.A., Bruno, G.F., et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 77 (2004), 496–499.
9. 9 Leyh, R.G., Kofidis, T., Strüber, M., et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg 125 (2003), 1426–1431.
10. 10 Gillman, P.K., A review of serotonin toxicity data: Implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59 (2006), 1046–1051.
11. 11 Petzer, A., Harvey, B.H., Wegener, G., Azure, B., et al. A metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol 258 (2012), 403–409.
12. 12 Shanmugam, G., Kent, B., Alsaiwadi, T., et al. Serotonin syndrome following cardiac surgery. Interact Cardiovasc Thorac Surg 7 (2008), 656–657.
13. 13 Grubb, K.J., Kennedy, J.L., Bergin, J.D., et al. The role of methylene blue in serotonin syndrome following cardiac transplantation: A case report and review of the literature. J Thorac Cardiovasc Surg 144 (2012), e113–116.
14. 14 Smith, C.J., Wang, D., Sgambelluri, A., et al. Serotonin syndrome following methylene blue administration during cardiothoracic surgery. J Pharm Pract 28 (2015), 207–211.
15. 15 Kofidis, T., Strüber, M., Wihelmi, M., et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thorac Cardiovasc Surg 122 (2001), 823–824.
16. 16 FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue (methylthioninium chloride) and serotonergic psychiatric medications. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm276119.htm. Accessed June 30th, 2015.
17. 17 Mills, K.C., Serotonin syndrome. A clinical update. Crit Care Clin 13 (1997), 763–783.
18. 18 Tso, M.M., Blatchford, K.L., Callado, L.F., et al. Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices. Neurochem Int 44 (2004), 1–7.
19. 19 Bernard, C, Frih, H, Pasquet, F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev 15:1 (2016), 82–92.
20. 20 Malignant Hyperthermia Association of the United States web page. Available at: MHAUS.org http://www.mhaus.org/healthcare-professionals. Accessed November 13th 2015.
21. 21 Glahn, K.P., Ellis, F.R., Halsall, P.J., et al. Recognizing and managing a malignant hyperthermia crisis: Guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 105 (2010), 417–420.
22. 22 Gurrera, R.J., Caroff, S.N., Cohen, A., et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72 (2011), 1222–1228.